TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Imugene ( (AU:IMU) ) has provided an announcement.
Imugene Limited announced the results of its Annual General Meeting, highlighting a significant shareholder dissent with 30.55% voting against the Remuneration Report, marking a ‘second strike’ under the Corporations Act 2001. Despite this, the Spill Resolution was not passed, with 84.06% voting against it, indicating continued support for the current board and management.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene is a clinical stage immuno-oncology company focused on developing innovative immunotherapies aimed at activating the immune system to combat cancer. Their pipeline includes CAR T cell therapy and oncolytic virotherapy, targeting both blood and solid tumors, with a vision to transform cancer treatment globally.
Average Trading Volume: 2,518,499
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$102.5M
Learn more about IMU stock on TipRanks’ Stock Analysis page.